Misonix Reports Fourth Quarter and Fiscal Year 2009 Financi...(2980746 63421 3352618 5359...),Health

Date:10/1/2009

2,980,746 63,421 3,352,618 535,912 Net income (loss) $2,177,195 ($2,350,329) $2,806,167 ($2,887,811) ========== =========== ========== =========== Loss per share-Basic from continuing operations ($0.11) ($0.35) ($0.08) ($0.50) Income per share- Basic from discontinued operations 0.43 0.01 0.48 0.09 Net income (loss) per share-basic $0.31 ($0.34) $0.40 ($0.41) ===== ====== ===== ====== Loss per share- Diluted from continuing operations ($0.11) ($0.35) ($0.08) ($0.50) Income per share- Diluted from discontinued operations 0.42 0.01 0.48 0.09 Net income (loss) per share-Diluted $0.31 ($0.34) $0.40 ($0.41) ===== ====== ===== ====== Weighted average common shares-basic 7,001,369 7,001,369 7,001,369 7,001,369 ========= ========= ========= ========= Weighted average common shares- diluted 7,001,369 7,001,369 7,001,369 7,001,369 ========= ========= ========= =========

SOURCE Misonix, Inc.

'/>"/>

SOURCE Misonix, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors